Related Experiment Video
Updated: May 13, 2026
Functional Manipulation of Maternal Gene Products Using In Vitro Oocyte Maturation in Zebrafish
Published on: April 22, 2017
Estrogen-suppressed in vitro maturation: a novel approach to in vitro maturation
Wendy S Vitek1, Jeannine Witmyer, Sandra A Carson
1Division of Reproductive Endocrinology and Infertility, Women and Infants Hospital of Rhode Island, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.
Objective:
To evaluate the laboratory and clinical outcomes of estrogen-suppressed in vitro maturation (ES-IVM), a novel IVM protocol that eliminates the need for FSH stimulation and cycle monitoring.
Design:
Case series.
Setting:
Academic infertility center.
Patient(S):
Eighteen infertile couples undergoing ES-IVM (n = 20). Eligible candidates included women ≤38 years old with either polycystic ovarian syndrome, antral follicle count ≥15, and/or history of ovarian hyperstimulation syndrome.
Intervention(S):
ES-IVM.
Main Outcomes Measure(S):
Oocyte yield, maturation, fertilization, embryo quality, implantation, clinical pregnancy, and live-birth rate were analyzed.
Result(S):
The average number of oocytes retrieved was 16.7 ± 5.9, with a 52.1% maturation rate and a 58% fertilization rate by intracytoplasmic sperm injection. The average number of embryos transferred was 2.85 ± 0.6. The implantation rate was 17.5%, the clinical pregnancy rate was 40%, and the live-birth rate was 40%.
Conclusion(S):
The efficiency of ES-IVM appears to be similar to natural cycle and low-stimulation IVM protocols with respect to laboratory and clinical outcomes, while eliminating the need for FSH stimulation and cycle monitoring.
Related Concept Videos
01:16In-vitro Mutagenesis
01:16In vitro Mutagenesis